Abstract
Objective
The efficacy and safety of tranexamic acid (TXA) on reducing blood loss and transfusion has been confirmed in primary total hip arthroplasty (THA). The main methods of administration includes intravenous, topical alone or combined use, and the most appropriated methods remains undecided. This study was aimed to compare the efficacy and safety of different methods of TXA following primary THA.
Methods
We prospectively collected patients' data through National Health Database from January 2013 to December 2016. The patients were divided into control group, intravenous group, topical group and combined group according to the different methods of TXA. The primary outcome was the incidence of transfusion and venous thromboembolism. Secondary outcomes were total blood loss, hemoglobin level on postoperative day 3 and decrease in hemoglobin, incidence of wound complications and other adverse events.
Results
A total of 7537 primary THA procedures were collected, 4102 with TXA, 3435 without TXA. 2847 (37.8%) patients received intravenous TXA alone, 235 (3.1%) patients received topical TXA alone and 1020 (13.5%) patients received combined use. The transfusion rate decreased from 33.07% to 12.7% with the use of TXA (p< 0.001). The transfusion rate was 30.21% in topical group, 10.68% in intravenous group, and 14.31% in combined group, with a significant difference between treatment groups (p< 0.01 for all). The hemoglobin on postoperative day 3 in control group was 91.24±17.09 g/L, which was significantly lower than that in topical group (101.38±16.71 g/L), intravenous group (102.79±32.37 g/L) and combined group (104.34±16.67 g/L, p<0.05 for all). The hemoglobin drop on POD 3 in control group was 38.07±18.10 g/L, which was significantly higher than that in topical group (30.02±17.11 g/L), intravenous group (29.35±16.05 g/L) and combined group (29.22±16.37 g/L, p<0.05 for all). The total blood loss in control group was (1377.74 ± 851.97 ml), which was significantly higher than that in topical group (1123.15±628.59 ml), intravenous group (971.08±671.39 ml) and combined group (946.4±724.82 ml, p<0.05 for all). A total of 14 DVT (0.41%) in control group, 4 patients (0.1%) in TXA group occurred DVT, and the difference was significant (0.10%, p= 0.006). Cardiac infarction occurred in 3 patients (0.04%), stroke occurred in 2 patients (0.03%), and 3 patients (0.04%) developed wound infection. No episode of PE or death occurred.
Conclusion
TXA was effective and safe to decrease blood loss and transfusion following primary THA no matter of intravenous, topical use alone or combined use. In order to achieve better hemostatic effect, intravenous or combined application was recommended if no contradictions were found.
